Search Results (4)

With accelerating urbanization, the outdoor thermal environment has become a critical factor affecting the thermal comfort of public spaces, particularly in high-density commercial districts and pedestrian-concentrated areas. To enhance thermal comfort and livability in public outdoor space, this study proposes a thermal demand-responsive design approach that integrates thermal conditions with pedestrian flow dynamics. A commercial pedestrian mall featuring semi-open public spaces and air-conditioned interior retail areas was selected as a case study. Computational Fluid Dynamics (CFD) simulations were conducted based on design-phase documentation and field measurements to model the thermal environment. The Universal Thermal Climate Index (UTCI) was employed to assess thermal comfort levels, and thermal discomfort was further quantified using the Heat Discomfort Index (HI). Simultaneously, pedestrian density distribution (λ) was analyzed using the agent-based simulation software MassMotion (Version 11.0). A demand of thermal comfort (DTC) index was developed by coupling UTCI-based thermal conditions with pedestrian density, enabling the spatial quantification of thermal demand across the whole commercial pedestrian mall. For example, in a sidewalk area parallel to the main street, several points exhibited high discomfort levels (HI = 0.95) but low pedestrian volume, resulting in DTC values approximately 0.2 units lower than adjacent zones with lower discomfort levels (HI = 0.7) but higher foot traffic. Such differences demonstrate how DTC can reveal priority areas for intervention. Key zones requiring thermal improvement were identified based on DTC values, providing a quantitative foundation for outdoor thermal environment design. This method provides both a theoretical foundation and a practical tool for the sustainable planning and optimization of urban public spaces. Full article

Canine leishmaniosis (CanL) is a growing health problem for which vaccination is a crucial tool for the control of disease. The successful development of an effective vaccine against this disease relies on eliciting a robust and enduring T-cell immune response involving the activation of CD4⁺ Th1 and CD8⁺ T-cells. This study aimed to evaluate the immunogenicity and prophylactic efficacy of a novel nanovaccine comprising a multi-epitope peptide, known as HisDTC, encapsulated in PLGA nanoparticles against Leishmania infantum infection in the murine model. The encapsulation strategy was designed to enhance antigen loading and sustain release, ensuring prolonged exposure to the immune system. Our results showed that mice immunized with PLGA-encapsulated HisDTC exhibited a significant reduction in the parasite load in the liver and spleen over both short and long-term duration. This reduction was associated with a cellular immune profile marked by elevated levels of pro-inflammatory cytokines, such as IFN-γ, and the generation of memory T cells. In conclusion, the current study establishes that PLGA-encapsulated HisDTC can promote effective and long-lasting T-cell responses against L. infantum in the murine model. These findings underscore the potential utility of multi-epitope vaccines, in conjunction with appropriate delivery systems, as an alternative strategy for CanL control. Full article

Zoonotic leishmaniases are a worldwide public health problem for which the development of effective vaccines remains a challenge. A vaccine against leishmaniases must be safe and affordable and should induce cross-protection against the different disease-causing species. In this context, the DNA vaccine pHisAK70 has been demonstrated to induce, in a murine model, a resistant phenotype against L. major, L. infantum, and L. amazonensis. Moreover, a chimeric multiepitope peptide, HisDTC, has been obtained by in silico analysis from the histone proteins encoded in the DNA vaccine and has showed its ability to activate a potent CD4⁺ and CD8⁺ T-cell protective immune response in mice against L. infantum infection. In the present study, we evaluated the plasmid DNA vaccine pHisAK70 in comparison with the peptide HisDTC (with and without saponin) against L. major and L. infantum infection. Our preliminary results showed that both formulations were able to induce a potent cellular response leading to a decrease in parasite load against L. infantum. In addition, the DNA candidate was able to induce better lesion control in mice against L. major. These preliminary results indicate that both strategies are potentially effective candidates for leishmaniases control. Furthermore, it is important to carry out such comparative studies to elucidate which vaccine candidates are the most appropriate for further development. Full article

Visceral leishmaniosis (VL) caused by Leishmania infantum is a disease with an increasing prevalence worldwide. Treatments are expensive, toxic, and ineffective. Therefore, vaccination seems to be a promising approach to control VL. Peptide-based vaccination is a useful method due to its stability, absence of local side effects, and ease of scaling up. In this context, bioinformatics seems to facilitate the use of peptides, as this analysis can predict high binding affinity epitopes to MHC class I and II molecules of different species. We have recently reported the use of HisAK70 DNA immunization in mice to induce a resistant phenotype against L. major, L. infantum, and L. amazonensis infections. In the present study, we used bioinformatics tools to select promising multiepitope peptides (HisDTC and AK) from the polyprotein encoded in the HisAK70 DNA to evaluate their immunogenicity in the murine model of VL by L. infantum. Our results revealed that both multiepitope peptides were able to induce the control of VL in mice. Furthermore, HisDTC was able to induce a better cell-mediated immune response in terms of reduced parasite burden, protective cytokine profile, leishmanicidal enzyme modulation, and specific IgG2a isotype production in immunized mice, before and after infectious challenge. Overall, this study indicates that the HisDTC chimera may be considered a satisfactory tool to control VL because it is able to activate a potent CD4⁺ and CD8⁺ T-cell protective immune responses. Full article